Related Experiment Video

Updated: Jun 5, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Modulation of tumor immunity by therapeutic monoclonal antibodies

Riad Abès1, Jean-Luc Teillaud

  • 1INSERM U.872/Cordeliers Research Center, 15, rue de l'Ecole de Medecine, Paris 75006, France. riadabes@hotmail.com

Cancer Metastasis Reviews
|January 27, 2011
PubMed

Insights

Therapeutic monoclonal antibodies (mAbs) not only target tumors directly but also harness the patient's immune system to build lasting adaptive immunity against cancer. This review explores how mAbs can enhance anti-tumor immune responses for improved cancer immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • The immune system's role in cancer surveillance and its impact on patient outcomes are well-established.
  • Therapeutic monoclonal antibodies (mAbs) have significantly improved survival and quality of life in various cancers.
  • Clinical responses to mAbs are heterogeneous and unpredictable, highlighting the need for deeper understanding.

Purpose of the Study:

  • To review the concept that therapeutic mAbs can induce long-lasting adaptive anti-tumor immunity.
  • To detail the cellular and molecular mechanisms underlying mAb-induced adaptive immune responses.
  • To discuss the integration of mAbs into broader immunotherapeutic strategies for cancer.

Main Methods:

  • Review of existing literature on immune surveillance in cancer.
  • Analysis of studies on therapeutic monoclonal antibody mechanisms of action.
  • Examination of cellular and molecular events in adaptive anti-tumor immunity induction by mAbs.

Main Results:

  • Therapeutic mAbs trigger immediate anti-tumor effects (e.g., receptor blockade, cytotoxicity).
  • mAbs also stimulate the host immune system to develop adaptive anti-tumor immunity.
  • This adaptive immunity contributes to long-lasting anti-tumor responses.

Conclusions:

  • Therapeutic monoclonal antibodies can initiate adaptive anti-tumor immune responses.
  • Understanding these mechanisms can optimize mAb use in combination immunotherapies.
  • Enhancing adaptive immunity via mAbs offers a promising avenue for cancer treatment.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...